Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer

BACKGROUND: Neoadjuvant immunotherapy, the focus of current research and treatment modality for long-term survival, has become one of the main options in supporting primary treatment interventions in early NSCLC. METHODS: This was a retrospective analysis of patients with locally resectable NSCLC wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yulong, Yan, Bo, Zhang, Ran, Zhao, Gang, You, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559199/
https://www.ncbi.nlm.nih.gov/pubmed/37809935
http://dx.doi.org/10.1016/j.heliyon.2023.e19818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559199/
https://www.ncbi.nlm.nih.gov/pubmed/37809935
http://dx.doi.org/10.1016/j.heliyon.2023.e19818

Ejemplares similares